Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Themis Biosyn reported audited results for the quarter and year ended March 31, 2025. Full-year operating income fell to Rs. 15,079.99 lakhs from Rs. 16,982.19 lakhs in FY24, a decline of about 11.2%, while net profit dropped to Rs. 4,877.17 lakhs from Rs. 5,916.32 lakhs, down roughly 17.6%. EPS for the year stood at Rs. 4.48 versus Rs. 5.43 in the previous year. The Board recommended a final dividend of Re. 0.67 per share (67% on face value of Re. 1), totaling Rs. 7.30 crore, subject to shareholder approval. The statutory auditor GMJ & Co. issued an unmodified (clean) opinion on the results. The Board also appointed M/s. KRS and Co. as Secretarial Auditor for five years and re-appointed M/s. Raja Dutta & Co. as Cost Auditor for FY26.
Sharper-than-revenue drop in profits points to margin pressure and softer demand, which is mildly negative for the stock in the short term, though the clean audit opinion and continued dividend payout signal financial stability.